GlassScriptPhysician profile
Joseph M Beck
NPI 1568441368
$16,477.05
in general payments reported to CMS, 2019-2025
71 companies · $3,737 in 2025
The $3,737 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,460 · 2020: $1,530 · 2021: $1,889 · 2022: $2,643 · 2023: $2,866 · 2024: $2,352 · 2025: $3,737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,755 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,755.05 |
| Education | $199.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,139.57 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $919.38 | 2019-2025 | Jakafi, Monjuvi, Niktimvo |
| Janssen Biotech, INC. | $910.65 | 2019-2025 | Rybrevant, Darzalex, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $861.37 | 2019-2025 | Imfinzi, Enhertu, Lynparza |
| Gilead Sciences, INC. | $820.32 | 2019-2025 | Biktarvy, Sunlenca |
| Novartis Pharmaceuticals Corporation | $727.45 | 2019-2025 | |
| Abbvie INC. | $708.57 | 2020-2025 | Venclexta |
| Celgene Corporation | $699.77 | 2019-2025 | Reblozyl, Pomalyst |
| Pfizer INC. | $611.56 | 2019-2025 | |
| Seagen INC. | $577.16 | 2020-2025 | Adcetris, Tukysa |
| Exelixis INC. | $557.17 | 2019-2025 | Cabometyx |
| Genentech USA, INC. | $525.04 | 2019-2025 | Tecentriq, Lunsumio, Polivy |
| Lilly USA, LLC | $451.33 | 2020-2025 | Jaypirca, Verzenio |
| Daiichi Sankyo INC. | $450.53 | 2023-2025 | Enhertu, Datroway |
| E.R. Squibb & Sons, L.L.C. | $432.95 | 2019-2025 | Opdivo, Opdualag |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $387.07 | 2021-2025 | Bavencio |
| Amgen INC. | $383.76 | 2019-2023 | Lumakras, Kyprolis, Nplate |
| Viiv Healthcare Company | $346.36 | 2019-2025 | Dovato |
| Genzyme Corporation | $327.86 | 2019-2024 | |
| Eisai INC. | $326.17 | 2022-2025 | |
| Astellas Pharma US INC | $288.38 | 2022-2025 | Xospata, Padcev, Xtandi |
| Pharmacyclics LLC, An Abbvie Company | $267.02 | 2019-2023 | Imbruvica |
| Glaxosmithkline, LLC. | $229.79 | 2023-2025 | Ojjaara, Zejula, Jemperli |
| Ipsen Biopharmaceuticals, INC | $210.74 | 2022-2025 | Onivyde, Somatuline Depot, Tazverik |
| Array Biopharma INC | $206.07 | 2021-2025 | Lorbrena, Mektovi, Braftovi |
| Aveo Pharmaceuticals, INC. | $205.30 | 2022-2025 | Fotivda |
| Regeneron Healthcare Solutions, INC. | $198.64 | 2023-2025 | Libtayo |
| Pharmaessentia USA Corporation | $190.79 | 2022-2025 | Besremi |
| Theratechnologies INC. | $176.76 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $166.32 | 2019-2025 | |
| Beigene USA, INC. | $153.38 | 2021-2024 | Brukinsa |
| Puma Biotechnology, INC. | $151.12 | 2019-2025 | |
| Janssen Products, LP | $130.49 | 2021-2022 | |
| Pharmacosmos Therapeutics INC. | $129.79 | 2023-2025 | Monoferric, Cosela |
| Sobi, INC | $127.29 | 2023-2025 | |
| Mirati Therapeutics, INC. | $116.20 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $90.73 | 2022-2025 | Ninlaro, Iclusig |
| Clovis Oncology, INC. | $88.83 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $79.61 | 2024-2025 | Orgovyx |
| Servier Pharmaceuticals LLC | $77.46 | 2025 | |
| Intuitive Surgical, INC. | $76.92 | 2024 | |
| Morphosys, US INC. | $69.89 | 2023 | Monjuvi |
| Epizyme, INC. | $68.23 | 2021-2022 | |
| Rigel Pharmaceuticals, INC. | $67.08 | 2021-2022 | |
| Beone Medicines USA, INC. | $66.46 | 2025 | Brukinsa, Tevimbra |
| Janssen Pharmaceuticals, INC | $65.74 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.78 | 2023-2025 | Gilotrif |
| Foundation Medicine, INC. | $61.47 | 2019 | |
| Fresenius Kabi USA, LLC | $47.93 | 2025 | Stimufend |
| Blueprint Medicines Corporation | $47.15 | 2025 | Ayvakit |
| G1 Therapeutics, INC. | $41.24 | 2022-2023 | Cosela |
| Lexicon Pharmaceuticals, INC. | $36.87 | 2020 | |
| Karyopharm Therapeutics INC. | $31.52 | 2023 | Xpovio |
| Alexion Pharmaceuticals, INC. | $30.75 | 2019-2025 | Ultomiris |
| Caris Mpi, INC. | $30.20 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $27.13 | 2023-2024 | Orserdu |
| Kyowa Kirin, INC. | $24.49 | 2020 | |
| Global Blood Therapeutics, INC. | $21.87 | 2022 | |
| Paratek Pharmaceuticals, INC. | $21.59 | 2020 | |
| Menarini Silicon Biosystems, INC. | $20.33 | 2024 | |
| Recordati_rare_diseases_inc. | $19.44 | 2024 | Sylvant |
| Geron Corporation | $17.48 | 2025 | Rytelo |
| Alnylam Pharmaceuticals INC. | $15.93 | 2025 | Givlaari |
| Amag Pharmaceuticals, INC. | $14.98 | 2022 | |
| Tesaro, INC. | $14.48 | 2019 | |
| Deciphera Pharmaceuticals INC. | $13.85 | 2025 | Qinlock, Romvimza |
| Dova Pharmaceuticals | $12.50 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$67.30 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.